Background: Eltrombopag is an orally bioavailable small molecule agonist of thrombopoietin receptor (TPO-R) that has been recently approved in the USA for treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP). The population pharmacokinetics of eltrombopag in healthy volunteers and patients with ITP has been previously described [1]. The model identified health status (healthy...

Objective Lusutrombopag is a thrombopoietin receptor agonist that improves thrombocytopenia in patients with chronic liver disease scheduled to undergo invasive procedures. However, information on the efficacy of repeated lusutrombopag treatment and factors associated scarce. We analyzed response lusutrombopag. Methods Thirty-nine who received before undergoing procedures were enrolled this ret...

Cyclic thrombocytopenia is a rare disorder characterized by periodic decreases and increases in platelet levels. Recent data suggest these fluctuations result from periodic failure of effective platelet production or periodic immune-mediated platelet destruction.’.’ However, the pathogenesis of this disorder is uncertain. We developed an enzyme-linked immunosorbent assay (ELISA) of serum thromb...